Table II.

Associations between BRAF^V600E mutation/phospho-MAPK/Mps1 and clinicopathological parameters in thyroid carcinomas.

	B-RAFV600E mutation (n=161)			Phospho-MAPK in tumor (n=60)			MpS1 in tumor (n=60)
Clinicopathological feature	+	−	P-value	+	−	P-value	+	−	P-value
No. (%)	54 (34%)	107 (67%)		2 (3%)	58 (97%)		47 (78%)	13 (22%)
Sex			0.514			>0.999			>0.999
Male	13	21		1	29		10	3
Female	41	86		1	29		37	10
Age, years			0.025			0.472			>0.999
>35	42	97		2	28		38	11
≤35	12	10		0	30		9	2
Smoking status			0.727			0.472			>0.999
Yes	4	5		0	30		2	1
No	50	102		2	28		45	12
Drinking status			0.190			0.472			>0.999
Yes	4	2		0	30		2	0
No	50	105		2	28		45	13
Familial history			0.211			0.472
Yes	2	0		0	30		0	0
No	52	107		2	28		47	13
Tumor grade			0.367			0.472
Papillocarcinoma	54	103		2	28		47	13
Non-papillocarcinoma	0	4		0	30		0	0
Pathological T stage			0.018			0.472			0.629
T1-T2	50	83		2	28		41	10
T3-T4	4	24		0	30		6	3
Pathological N stage			0.004			0.472			0.898
N0	30	34		0	30		28	8
N1	24	73		2	28		19	5
Clinical M						0.472
M0	54	107		2	28		47	13
M1	0	0		0	30		0	0
Pathological stage			0.585			0.472			>0.999
I–II	34	72		0	30		33	9
III–IV	20	35		2	28		14	4

BRAF, B-Raf proto-oncogene serine/threonine kinase; phospho-MAPK, phospho-mitogen-activated protein kinases; T, tumor; N, lymph node; M, metastasis.